Indivior Pharmaceuticals Inc (INDV) Stock | INDV Stock Price & Analysis

Feed

INDV

Indivior Pharmaceuticals Inc INDV · NASDAQ

$36.28 +2.57% (+$0.91)

Summary

75 / 100 · Bulios Score

Valuation 64Growth 72Profitability 76Quality 97Debt 81Stability 53

What speaks for it

Out of every 100 USD of revenue, 33 USD is left as net profit.
It earns 95 USD a year on every 100 USD of invested capital.
Revenue grew by 11% a year over the last 3 years.

What to watch

It pays out more in dividends than it earns: 225% of profit.
The share price is above the Bulios Fair Price.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Is it expensive?

Looks expensive

Bulios Fair Price

Current price $36.28

P/E today 10.1 96% lower

5-year average P/E 287.1

P/E today 10.1

Drug Manufacturers - Specialty & Generic industry median

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 10.1 USD for 1 USD of yearly profit. Over the last five years it was 287.1 USD on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

791M

901M

1.1B

1.2B

1.3B

1.4B

2021202220232024202520262027

Diluted EPS (USD)

$1.31

-$0.37

$0.01

$0.02

$1.64

$4.04

$4.34

2021202220232024202520262027

Analyst estimate

Revenue grew by 14% a year over 5 years. Over the last 3 years it grew by 11% a year.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Cost of sales 15 USD
Research and development 3.6 USD
Sales and administration 38 USD
Taxes and other 11 USD
Net profit 33 USD

Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10.0 USD

Out of every 100 USD of revenue, 33 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Cash and short-term investments $305.0M

Debt $501.0M

Free cash flow over 12 months $31.0M

Repaying all its debt would take 16.2 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.

Financial health in detail

Does it pay a dividend?

High, at risk

Yield: 22.41%
Paid out of profit: 225%

You receive 8.13 per share a year. The payout is more than the company can comfortably cover.

Dividends in detail

What do analysts expect?

Mildly positive

Buy 4
Hold 0
Sell 0

Today's price within the analysts' price targets

Today's price $36.28 Average target $48

$36.28 $53

The average target of $48 is 32% above today's price. 100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

Reportable Segment 100%

By region

UNITED STATES 100%

Reportable Segment brings in 100% of revenue.

Segments in detail